Table 2 Multivariable analysis of the variables associated with MET alterations*
MET wild type, N = 407 | MET altered, N = 31 | Univariable | Multivariable | |||||
|---|---|---|---|---|---|---|---|---|
Characteristics | Wald | Odds ratio (CI 95%) | P value | Wald | Odds ratio (CI 95%) | P value | ||
Type of cancer | ||||||||
Brain (n = 109)** | 107 (26.3%) | 2 (6.5%) | 4.94 | 0.19 (0.05–0.83) | 0.026** | – | – | – |
Lung (n = 102) | 90 (22.1%) | 12 (38.7%) | 4.26 | 2.22 (1.04–4.76) | 0.039 | – | – | – |
Presence of metastasis or recurrence at the time of blood draw (n = 312) | 284 (69.8%) | 28 (90.3%) | 5.13 | 4.0 (1.2–14.3) | 0.024 | – | – | – |
Genetic alteration type | ||||||||
TP53 (n = 149) | 129 (31.7%) | 20 (64.5%) | 12.2 | 3.85 (1.82–8.33) | < 0.001 | 10.9 | 3.7 (1.7–8.3) | 0.001 |
EGFR (n = 53) | 43 (10.6%) | 10 (32.4%) | 11.2 | 4.0 (1.79–9.1) | 0.001 | – | – | – |
PIK3CA (n = 42) | 35 (8.6%) | 7 (22.6%) | 5.93 | 3.1 (1.25–7.7) | 0.015 | – | – | – |
BRAF (n = 27) | 22 (5.4%) | 5 (16.1%) | 5.14 | 3.3 (1.2–10.0) | 0.023 | – | – | – |
ARID1A (n = 19) | 15 (3.7%) | 4 (12.9%) | 5.14 | 3.85 (1.2–12.5) | 0.023 | – | – | – |
ALK (n = 14) | 11 (2.7%) | 3 (9.7%) | 3.94 | 3.85 (1.02–14.3) | 0.047 | – | – | – |
PTEN (n = 9) | 6 (1.5%) | 3 (9.7%) | 7.72 | 7.1 (1.7–33.3) | 0.007 | 9.12 | 11.1 (2.3–50.0) | 0.003 |
Metastatic sites | ||||||||
Lymph node (n = 139) | 123 (30.2%) | 16 (51.6%) | 5.77 | 2.4 (1.2–5.3) | 0.016 | – | – | – |
Bone (n = 102) | 88 (21.6%) | 14 (45.2%) | 8.26 | 2.9 (1.4–6.3) | 0.004 | 7.34 | 2.9 (1.35–6.25) | 0.007 |
No metastases (n = 147)** | 145 (35.6%) | 2 (6.5%) | 7.96 | 0.13 (0.03–0.5) | 0.005** | – | – | – |